<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35128793</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Serum asymmetric dimethylarginine level correlates with the progression and prognosis of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1410</StartPage><EndPage>1416</EndPage><MedlinePgn>1410-1416</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15254</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">The aim was to investigate the association between serum asymmetric dimethylarginine (ADMA) levels and the progression and prognosis of amyotrophic lateral sclerosis (ALS), and to compare cerebrospinal fluid (CSF) and serum ADMA levels with other biomarkers of ALS.</AbstractText><AbstractText Label="METHODS">Serum ADMA levels of sporadic ALS patients (n&#xa0;=&#xa0;68), disease control patients (n&#xa0;=&#xa0;54) and healthy controls (n&#xa0;=&#xa0;20) were measured using liquid chromatography tandem mass spectrometry. Correlations of the ADMA level and other markers (nitric oxide and neurofilament light chain levels) were analyzed. Changes in the ALS Functional Rating Scale Revised (ALSFRS-R) score from the onset of disease (ALSFRS-R pre-slope) was used to assess disease progression. Survival was evaluated using the Cox proportional hazards model and Kaplan-Meier analysis.</AbstractText><AbstractText Label="RESULTS">The serum ADMA level was substantially higher in patients with ALS than in healthy controls and disease controls. Serum ADMA level correlated with CSF ADMA level (r&#xa0;=&#xa0;0.591, p&#xa0;&lt;&#xa0;0.0001) and was independently associated with the ALSFRS-R pre-slope (r&#xa0;=&#xa0;0.505, p&#xa0;&lt;&#xa0;0.0001). Patients with higher serum ADMA levels had less favorable prognoses. CSF ADMA level significantly correlated with CSF neurofilament light chain level (r&#xa0;=&#xa0;0.456, p&#xa0;=&#xa0;0.0002) but not with nitric oxide level (r&#xa0;=&#xa0;0.194, p&#xa0;=&#xa0;0.219).</AbstractText><AbstractText Label="CONCLUSION">Serum ADMA level is an independent biomarker of ALS disease progression and prognosis and reflects the degree of motor neuron degeneration.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ikenaka</LastName><ForeName>Kensuke</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5559-1966</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Joint Research Facilities Support, Fujita Health University, Toyoake, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hotta</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagano</LastName><ForeName>Seiichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torii</LastName><ForeName>Ryota</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakuda</LastName><ForeName>Keita</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatebe</LastName><ForeName>Harutsugu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>T &amp; T Brothers Corporation, Chiba, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atsuta</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Aichi Medical University School of Medicine, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguirre</LastName><ForeName>Cesar</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Yasuyoshi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baba</LastName><ForeName>Kousuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokuda</LastName><ForeName>Takahiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>T &amp; T Brothers Corporation, Chiba, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9453-9311</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Kazunori</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Research Division of Dementia and Neurodegenerative Disease, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aichi Medical University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mochizuki</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>63CV1GEK3Y</RegistryNumber><NameOfSubstance UI="C018524">N,N-dimethylarginine</NameOfSubstance></Chemical><Chemical><RegistryNumber>94ZLA3W45F</RegistryNumber><NameOfSubstance UI="D001120">Arginine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001120" MajorTopicYN="N">Arginine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">dimethylarginine</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>7</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35128793</ArticleId><ArticleId IdType="pmc">PMC9305138</ArticleId><ArticleId IdType="doi">10.1111/ene.15254</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chio A, Calvo A, Moglia C, Mazzini L, Mora G. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82(7):740&#x2010;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Atsuta N, Hirakawa A, et al. A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. J Neurol Neurosurg Psychiatry. 2016;87(8):851&#x2010;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">26746183</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenaka K, Atsuta N, Maeda Y, et al. Increase of arginine dimethylation correlates with the progression and prognosis of ALS. Neurology. 2019;92(16):e1868&#x2010;e1877.</Citation><ArticleIdList><ArticleId IdType="pubmed">30867270</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Tokuda E. Aggregation of FET proteins as a pathological change in amyotrophic lateral sclerosis. Adv Exp Med Biol. 2017;925:1&#x2010;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">27311318</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanikawa C, Ueda K, Suzuki A, et al. Citrullination of RGG motifs in FET proteins by PAD4 regulates protein aggregation and ALS susceptibility. Cell Rep. 2018;22(6):1473&#x2010;1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">29425503</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack GE, Luisier R, Taha DM, et al. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain. 2019;142(9):2572&#x2010;2580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735815</ArticleId><ArticleId IdType="pubmed">31368485</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenaka K, Ishigaki S, Iguchi Y, et al. Characteristic features of FUS inclusions in spinal motor neurons of sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2020;79(4):370&#x2010;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">32142134</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsuta N, Watanabe H, Ito M, et al. Development of a telephone survey system for patients with amyotrophic lateral sclerosis using the ALSFRS&#x2010;R (Japanese version) and application of this system in a longitudinal multicenter study. Brain Nerve. 2011;63(5):491&#x2010;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">21515929</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A, Nagel G, Peter RS, et al. Association of serum retinol&#x2010;binding protein 4 concentration with risk for and prognosis of amyotrophic lateral sclerosis. JAMA Neurol. 2018;75(5):600&#x2010;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885207</ArticleId><ArticleId IdType="pubmed">29482216</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu T, Bokuda K, Kimura H, et al. Sensory cortex hyperexcitability predicts short survival in amyotrophic lateral sclerosis. Neurology. 2018;90(18):e1578&#x2010;e1587.</Citation><ArticleIdList><ArticleId IdType="pubmed">29602913</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Atsuta N, Watanabe H, et al. Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2013;84(12):1365&#x2010;1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">23933739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy KJ, Simandan TL, Dix TA. A facile route to cyclic and acyclic alkyl&#x2010;arginines. Synthetic Commun. 1998;28(4):741&#x2010;746.</Citation></Reference><Reference><Citation>Shinomoto M, Kasai T, Tatebe H, et al. Plasma neurofilament light chain: a potential prognostic biomarker of dementia in adult Down syndrome patients. PLoS One. 2019;14(4):e0211575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450630</ArticleId><ArticleId IdType="pubmed">30951523</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T, Kojima Y, Ohmichi T, et al. Combined use of CSF NfL and CSF TDP&#x2010;43 improves diagnostic performance in ALS. Ann Clin Transl Neurol. 2019;6(12):2489&#x2010;2502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6917342</ArticleId><ArticleId IdType="pubmed">31742901</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenaka K, Atsuta N, Maeda Y, et al. Increase of arginine dimethylation correlates with the progression and prognosis of ALS. Neurology. 2019;92:e1868&#x2010;e1877.</Citation><ArticleIdList><ArticleId IdType="pubmed">30867270</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66(6):852&#x2010;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol. 2012;19(12):1561&#x2010;1567.</Citation><ArticleIdList><ArticleId IdType="pubmed">22680408</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A, Martinelli I, Bello L, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017;74(5):525&#x2010;532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RA, Gray E, Lu CH, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol. 2015;2(7):748&#x2010;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4531057</ArticleId><ArticleId IdType="pubmed">26273687</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada S, Hashizume A, Hijikata Y, et al. Ratio of urinary N&#x2010;terminal titin fragment to urinary creatinine is a novel biomarker for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92(10):1072&#x2010;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">33737450</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>